Trillium Therapeutics Inc. (NASDAQ:TRIL)
Industry: Healthcare

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; and epidermal growth factor receptor antagonist, which is in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

Current Quote*
Last: $0.697
Change: 0.035
Book: $7.209
Volume: 1,033,425

As Of: 03/20 13:34 ET
*Quotes delayed by 20min.

Graphs for TRIL


3 Month Graph


6 Month Graph


1 Year Graph